Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Earnings Results, Misses Expectations By $0.23 EPS

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) posted its quarterly earnings data on Tuesday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23), FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Trading Down 5.2%

Shares of Damora Therapeutics, Inc. Common Stock stock traded down $1.27 during trading hours on Tuesday, reaching $23.09. 520,843 shares of the company’s stock were exchanged, compared to its average volume of 254,854. The stock has a market cap of $1.39 billion, a P/E ratio of -1.91 and a beta of 1.50. The company has a 50 day moving average of $26.02 and a two-hundred day moving average of $23.72. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33.

Wall Street Analysts Forecast Growth

DMRA has been the topic of several recent research reports. Guggenheim reissued a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective for the company. Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price on the stock. UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.40.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently bought and sold shares of DMRA. Ikarian Capital LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $6,574,000. Jain Global LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,774,000. Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,772,000. Boothbay Fund Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,204,000. Finally, Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $100,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.